Fast Five Quiz: Risk for Diabetic Nephropathy Progression

A. Brent Alper, Jr, MD, MPH


March 22, 2022

ACE inhibitors reduce the risk for progression of overt type 1 diabetic nephropathy to end-stage renal disease, and in patients with type 1 diabetes with microalbuminuria to overt nephropathy.

GLP-1 receptor antagonists have been shown to reduce albuminuria only, and their ability to slow progression to end-stage renal disease is not clear.

Learn more about slowing the progression of diabetic nephropathy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.